196 related articles for article (PubMed ID: 23078230)
1. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.
Kameshima H; Tsuruma T; Kutomi G; Shima H; Iwayama Y; Kimura Y; Imamura M; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Kanaseki T; Sato N; Hirata K
Cancer Sci; 2013 Jan; 104(1):124-9. PubMed ID: 23078230
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
[TBL] [Abstract][Full Text] [Related]
3. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.
Tanaka T; Kitamura H; Inoue R; Nishida S; Takahashi-Takaya A; Kawami S; Torigoe T; Hirohashi Y; Tsukamoto T; Sato N; Masumori N
Clin Dev Immunol; 2013; 2013():262967. PubMed ID: 24363758
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
[TBL] [Abstract][Full Text] [Related]
5. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
[TBL] [Abstract][Full Text] [Related]
6. Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
Kobayashi J; Torigoe T; Hirohashi Y; Idenoue S; Miyazaki A; Yamaguchi A; Hiratsuka H; Sato N
J Transl Med; 2009 Jan; 7():1. PubMed ID: 19123955
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.
Honma I; Kitamura H; Torigoe T; Takahashi A; Tanaka T; Sato E; Hirohashi Y; Masumori N; Tsukamoto T; Sato N
Cancer Immunol Immunother; 2009 Nov; 58(11):1801-7. PubMed ID: 19294381
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
Shima H; Tsurita G; Wada S; Hirohashi Y; Yasui H; Hayashi H; Miyakoshi T; Watanabe K; Murai A; Asanuma H; Tokita S; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Nakae Y; Sugita O; Ito YM; Ota Y; Kimura Y; Kutomi G; Hirata K; Mizuguchi T; Imai K; Takemasa I; Sato N; Torigoe T
Cancer Sci; 2019 Aug; 110(8):2378-2385. PubMed ID: 31218770
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.
Tsuruma T; Iwayama Y; Ohmura T; Katsuramaki T; Hata F; Furuhata T; Yamaguchi K; Kimura Y; Torigoe T; Toyota N; Yagihashi A; Hirohashi Y; Asanuma H; Shimozawa K; Okazaki M; Mizushima Y; Nomura N; Sato N; Hirata K
J Transl Med; 2008 May; 6():24. PubMed ID: 18471305
[TBL] [Abstract][Full Text] [Related]
10. Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine.
Shima H; Kutomi G; Satomi F; Imamura M; Kimura Y; Mizuguchi T; Watanabe K; Takahashi A; Murai A; Tsukahara T; Kanaseki T; Hirohashi Y; Iwayama Y; Tsuruma T; Kameshima H; Sato N; Torigoe T; Takemasa I
Cancer Immunol Immunother; 2018 Oct; 67(10):1603-1609. PubMed ID: 30069687
[TBL] [Abstract][Full Text] [Related]
11. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E
Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer.
Tsuruma T; Hata F; Torigoe T; Furuhata T; Idenoue S; Kurotaki T; Yamamoto M; Yagihashi A; Ohmura T; Yamaguchi K; Katsuramaki T; Yasoshima T; Sasaki K; Mizushima Y; Minamida H; Kimura H; Akiyama M; Hirohashi Y; Asanuma H; Tamura Y; Shimozawa K; Sato N; Hirata K
J Transl Med; 2004 Jun; 2(1):19. PubMed ID: 15193151
[TBL] [Abstract][Full Text] [Related]
14. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
15. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
17. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
Becker JC; Andersen MH; Hofmeister-Müller V; Wobser M; Frey L; Sandig C; Walter S; Singh-Jasuja H; Kämpgen E; Opitz A; Zapatka M; Bröcker EB; Thor Straten P; Schrama D; Ugurel S
Cancer Immunol Immunother; 2012 Nov; 61(11):2091-103. PubMed ID: 22565484
[TBL] [Abstract][Full Text] [Related]
18. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer.
Asahara S; Takeda K; Yamao K; Maguchi H; Yamaue H
J Transl Med; 2013 Nov; 11():291. PubMed ID: 24237633
[TBL] [Abstract][Full Text] [Related]
20. [Anti-apoptosis protein, survivin-2B-derived peptide vaccine therapy].
Tsuruma T; Torigoe T; Hata F; Furuhata T; Sato N; Hirata K
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1634-6. PubMed ID: 15553667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
